HC Wainwright Brokers Decrease Earnings Estimates for RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at HC Wainwright decreased their Q1 2027 earnings estimates for Ultragenyx Pharmaceutical in a research report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of $0.27 per share for the quarter, down from their prior forecast of $0.28. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($4.61) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q2 2027 earnings at $1.18 EPS, Q3 2027 earnings at $1.54 EPS, Q4 2027 earnings at $2.63 EPS and FY2027 earnings at $5.61 EPS.

A number of other research firms have also issued reports on RARE. Barclays cut their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Wall Street Zen lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday. Morgan Stanley upped their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, April 16th. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research note on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $60.41.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $26.30 on Tuesday. Ultragenyx Pharmaceutical has a 52-week low of $18.29 and a 52-week high of $42.37. The company’s 50 day simple moving average is $22.81 and its 200-day simple moving average is $26.68. The firm has a market capitalization of $2.59 billion, a P/E ratio of -4.30 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. During the same quarter in the prior year, the firm earned ($1.57) EPS. The firm’s revenue was down 2.2% compared to the same quarter last year.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently modified their holdings of RARE. Assetmark Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares during the period. Huntington National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares during the period. Leonteq Securities AG boosted its holdings in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $39,000. 97.67% of the stock is owned by institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 8,135 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the sale, the executive vice president directly owned 76,346 shares of the company’s stock, valued at $1,740,688.80. The trade was a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Howard Horn sold 8,409 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the sale, the chief financial officer directly owned 86,669 shares of the company’s stock, valued at $1,967,386.30. This represents a 8.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 111,522 shares of company stock worth $2,543,214. 5.20% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.